Polycyclic aromatic hydrocarbon-DNA adducts in prostate and biochemical recurrence after prostatectomy

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 750-757

  Rybicki, Benjamin A ^a,d   Neslund Dudas, Christine ^a   Bock, Cathryn H ^a   Rundle, Andrew ^b   Savera, Adnan T ^a   Yang, James J ^a   Nock, Nora L ^c   Tang, Deliang ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University Mailman School of Public Health ^*  (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CELL LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA ADDUCT; EUROPEAN AMERICAN; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; TUMOR CELL; UNITED STATES;

AGED; DNA ADDUCTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYCYCLIC HYDROCARBONS, AROMATIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 38949145020     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0986     Document Type: Article

References (55)

1. Polycyclic aromatic hydrocarbon carcinogenesis: structure-activity relationships. Boca Raton: CRC Press; 1988.
2. Miller EC, Miller JA. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer 1981;47:2327-45.
3. Rogan EG, Devanesan PD, RamaKrishna NV, et al. Identification and quantitation of benzo(a)pyrene-DNA adducts formed inmouse skin. Chem Res Toxicol 1993;6:356-63.
4. Wang CY, Debiec-Rychter M, Schut HA, et al. N-Acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis 1999;20:1591-5.
5. Williams JA, Martin FL, Muir GH, Hewer A, Grover PL, Phillips DH. Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis 2000;21:1683-9.
6. Kooiman GG, Martin FL, Williams JA, Grover PL, Phillips DH, Muir GH. The influence of dietary and environmental factors on prostate cancer risk. Prostate Cancer Prostatic Dis 2000;3:256-8.
7. Rybicki BA, Rundle A, Savera AT, Sankey SS, Tang D. Polycyclic aromatic hydrocarbon-DNA adducts in prostate cancer. Cancer Res 2004;64:8854-9.
8. Nock NL, Tang D, Rundle A, et al. Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Cancer Epidemiol Biomarkers Prev 2007;16:1236-45.
9. Krstev S, Baris D, Stewart P, et al. Occupational risk factors and prostate cancer in U.S. blacks and whites. Am J Ind Med 1998;34:421-30.
10. Brown DA, Delzell E. Motor vehicle manufacturing and prostate cancer. Am J Ind Med 2000;38:59-70.
11. Aronson KJ, Siemiatycki J, Dewar R, Gerin M. Occupational risk factors for prostate cancer: results from a case-control study in Montreal, Quebec, Canada. Am J Epidemiol 1996;143:363-73.
12. Boers D, Zeegers MP, Swaen GM, Kant I, van den Brandt PA. The influence of occupational exposure to pesticides, polycyclic aromatic hydrocarbons, diesel exhaust, metal dust, metal fumes, and mineral oil on prostate cancer: a prospective cohort study. Occup Environ Med 2005;62:531-7.
13. Rybicki BA, Neslund-Dudas C, Nock NL, et al. Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism. Cancer Detect Prev 2006;30:412-22.
14. Gammon MD, Santella RM, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev 2002;11:677-85.
15. Nock NL, Liu X, Cicek MS, et al. Polymorphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:756-61.
16. Phillips DH. Polycyclic aromatic hydrocarbons in the diet.Mutat Res 1999;443:139-47.
17. Rodgman A, Smith CJ, Perfetti TA. The composition of cigarette smoke: a retrospective, with emphasis on polycyclic components. Hum Exp Toxicol 2000;19:573-95.
18. Hickey K, Do KA, Green A. Smoking and prostate cancer. Epidemiol Rev 2001;23:115-25.
19. Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 2003;12:604-9.
20. Giles GG, Severi G, McCredie MR, et al. Smoking and prostate cancer: findings from an Australian case-control study. Ann Oncol 2001;12:761-5.
21. 105Val polymorphism, cigarette smoking and prostate cancer. Cancer Detect Prev 2004;28:368-74.
22. Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev 2001;23:72-81.
23. Cross AJ, Peters U, Kirsh VA, et al. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res 2005;65:11779-84.
24. Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003;62 Suppl 1:19-35.
25. Jana NR, Sarkar S, Ishizuka M, Yonemoto J, Tohyama C, Sone H. Comparative effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on MCF-7, RL95-2, and LNCaP cells: role of target steroid hormones in cellular responsiveness to CYP1A1 induction. Mol Cell Biol Res Commun 2000;4:174-80.
26. Cicek MS, Liu X, Casey G, Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11α in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2005;14:2173-7.
27. Rundle A, Tang D, Hibshoosh H, et al. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis 2000;21:1281-9.
28. Zhang YJ, Hsu TM, Santella R. Immunoperoxidase detection of polycyclic aromatic hydrocarbon-DNA adducts in oral mucosa cells of smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 1995;4:133-8.
29. Zenzes MT, Puy LA, Bielecki R, Reed TE. Detection of benzo(a) pyrene diol epoxide-DNA adducts in embryos from smoking couples: evidence for transmission by spermatozoa. Mol Hum Reprod 1999;5:125-31.
30. Zenzes MT, Puy LA, Bielecki R. Immunodetection of benzo(a)pyrene adducts in ovarian cells of women exposed to cigarette smoke. Mol HumReprod 1998;4:159-65.
31. Romano G, Sgambato A, Boninsegna A, et al. Evaluation of polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral cells by an immunohistochemical assay. Cancer Epidemiol Biomarkers Prev 1999;8:91-6.
32. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376-85.
33. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61:365-9.
34. SAS Institute, Inc. SAS/STATuser's guide, version 8, vol. 3. Cary (NC): SAS Institute Inc.; 1989. p. 4797-828.
35. Wingo PA, Ries LA, Parker SL, Heath CW, Jr. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 1998;7:271-82.
36. Merrill RM, Bird JS. Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control 2002;13:435-43.
37. Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 2005;23:441-7.
38. Gyorffy E, Anna L, Gyori Z, et al. DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by 32P-postlabelling and immunoassay. Carcinogenesis 2004;25:1201-9.
39. Banaszewski J, Szmeja Z, Szyfter W, Szyfter K, Baranczewski P, Moller L. Analysis of aromatic DNA adducts in laryngeal biopsies. Eur Arch Otorhinolaryngol 2000;257:149-53.
40. Li D, Firozi PF, Zhang W, et al. DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res 2002;513:37-48.
41. Chen SY, Wang LY, Lunn RM, et al. Polycyclic aromatic hydrocarbon-DNA adducts inliver tissues of hepatocellular carcinoma patients and controls. Int J Cancer 2002;99:14- 21.
42. Sterling KM, Jr., Cutroneo KR. Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. J Cell Biochem 2004;91:423-9.
43. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res 2004;64:8526-33.
44. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000;164:716-21.
45. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
46. Denissenko M, Pao A, Tang M, Pfiefer G. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in p53. Science 1996;274:430-2.
47. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92:803-11.
48. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM. Specificity of 17β-oestradiol and benzo (a)pyrene oxidation by polymorphic human cytochrome P4501B1variants substituted at residues 48, 119 and 432. Xenobiotica 2001;31:163-76.
49. Tokizane T, Shiina H, Igawa M, et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 2005;11:5793-801.
50. Hu JJ, Hall MC, Grossman L, et al. Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res 2004;64:1197-201.
51. Lockett KL, Hall MC, Clark PE, et al. DNA damage levels in prostate cancer cases and controls. Carcinogenesis 2006;27:1187-93.
52. Rundle A, Schwartz S. Issues in the epidemiological analysis and interpretation of intermediate biomarkers. Cancer Epidemiol Biomarkers Prev 2003;12:491-6.
53. Peluso M, Munnia A, Hoek G, et al. DNA adducts and lung cancer risk: a prospective study. Cancer Res 2005;65:8042-8.
54. Magagnotti C, Pastorelli R, Pozzi S, Andreoni B, Fanelli R, Airoldi L. Genetic polymorphisms and modulation of 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine (PhIP)-DNA adducts in human lymphocytes. Int J Cancer 2003;107:878-84.
55. Weiserbs KF, Jacobson JS, Begg MD, et al. A cross-sectional study of polycyclic aromatic hydrocarbon-DNA adducts and polymorphism of glutathione S-transferases among heavy smokers by race/ethnicity. Biomarkers 2003;8:142-55.